Intranasal administration of human recombinant BDNF improved depressive-like behavior in transgenic mice [97], while intranasal administration of neuropeptide Y led to increased expression of BDNF and reduced HD neuropathology in R6/2 mice [98]. The gene discussed is BDNF; the disease is Huntington disease.